Korro Bio
CompanyUnited States
Korro Bio develops one asset, in phase 1 (KRRO-121 in hepatic encephalopathy). Mostly oligonucleotide; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1GalNAc-conjugated RNA-editing oligonucleotide targeting transcripts to correct urea cycle defects
Phase 1, Oligonucleotide, hepatic encephalopathy, hyperammonemia in patients with urea cycle disorders
Full company profiles: pipeline, trials, funding and people.